Simeone and Fakih Detail Research Objectives With A2B530 in

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

Related Keywords

California , United States , New York , Marwang Fakih , Judy Bernard Briskin , Dianem Simeone , Kyle Doherty , Gastrointestinal Gi Cancer Program , Grossman School Of Medicine , Facebook , Judy Bernard Briskin Center , Perlmutter Cancer Center , Translational Research , Linkedin , Clinical Research At City Of Hope , Twitter , Pancreatic Cancer Center , Clinical Research , Department Of Surgery , Department Of Pathology , Department Of Medical Oncology Therapeutics Research , Live On Air , Isaac Perlmutter Professor , Bernard Briskin Distinguished Director , Medical Oncology , Therapeutics Research , Cancer Program , Bernard Briskin Center , Onclive On Air , Apple Podcasts , Google Podcasts , Amazon Music , D , Basecamp 1 Study , Nct04981119 , Everest 1 Study , Nct05736731 , A2b530 , Patients With Cea Expressing Solid Tumors , Nyu Grossman School Of Medicine , City Of Hope ,